{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-223967","form_type":"8-K","ticker":"CVSI","cik":"0001510964","company_name":"CV Sciences, Inc.","filed_at":"2026-05-14T20:04:49+00:00","discovered_at":"2026-05-14T20:06:00.351807+00:00","generated_at":"2026-05-14T21:02:04.596714+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"CV Sciences Q1 revenue down 11.4% to $3.2M; adjusted EBITDA loss narrows to $0.1M","bullets":["Revenue $3.2M (down 11.4% YoY); unit sales down 12.2%, partially offset by minor price increases.","Gross margin improved to 48.9% (from 46.0% YoY); operating loss $0.3M vs prior year operating income due to $0.5M payroll tax reversal.","Adjusted EBITDA loss of $0.1M vs $0.3M loss in Q1 2025; cash balance $0.3M at quarter end.","Completed debt restructuring to strengthen financial position; launched EMPOWR plant-based protein/creatine formula.","New products launched since Jan 2023 contributed 43% of Q1 net revenue; 45 new products introduced."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-223967","json":"https://secwatch.observer/filing/0001193125-26-223967.json","markdown":"https://secwatch.observer/filing/0001193125-26-223967.md","text":"https://secwatch.observer/filing/0001193125-26-223967.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1510964/000119312526223967/0001193125-26-223967-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1510964/000119312526223967/cvsi-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:02:04.596714+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a35077e998d3dcce05abc1ca25515d8b6874a78","claim":"CV Sciences, Inc. reported the quarter ended March 31, 2026 results: revenue $3.2 million.","evidence_excerpt":"Generated revenue of $3.2 million for the first quarter 2026 compared to $3.6 million for the first quarter 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1510964/000119312526223967/0001193125-26-223967-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Revenue","value":"$3.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}